OptiNose (NASDAQ:OPTN) Lowered to “Hold” Rating by Lake Street Capital

by · The Markets Daily

Lake Street Capital downgraded shares of OptiNose (NASDAQ:OPTN – Free Report) from a buy rating to a hold rating in a research note released on Thursday, MarketBeat Ratings reports. They currently have $9.00 target price on the stock, down from their prior target price of $17.00.

Separately, HC Wainwright boosted their target price on shares of OptiNose from $5.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd.

Get Our Latest Stock Report on OPTN

OptiNose Stock Up 52.5 %

Shares of OPTN stock opened at $9.15 on Thursday. The stock has a market cap of $92.05 million, a price-to-earnings ratio of -2.18 and a beta of -0.30. OptiNose has a fifty-two week low of $4.82 and a fifty-two week high of $25.80. The firm’s 50 day moving average price is $5.88 and its two-hundred day moving average price is $8.22.

Insider Transactions at OptiNose

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the transaction, the chief executive officer now directly owns 126,931 shares of the company’s stock, valued at approximately $671,464.99. The trade was a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 8,213 shares of company stock valued at $43,643. Corporate insiders own 2.30% of the company’s stock.

Institutional Trading of OptiNose

Several institutional investors have recently added to or reduced their stakes in the stock. State Street Corp raised its holdings in OptiNose by 14.2% in the third quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after acquiring an additional 42,500 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in OptiNose in the third quarter valued at $61,000. Massachusetts Financial Services Co. MA raised its holdings in OptiNose by 5.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company’s stock valued at $2,061,000 after acquiring an additional 155,329 shares in the last quarter. Geode Capital Management LLC raised its holdings in OptiNose by 33.7% in the third quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company’s stock valued at $870,000 after acquiring an additional 326,918 shares in the last quarter. Finally, Acorn Capital Advisors LLC acquired a new stake in OptiNose in the fourth quarter valued at $2,824,000. 85.60% of the stock is owned by institutional investors and hedge funds.

About OptiNose

(Get Free Report)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.

See Also